Extended Data Fig. 7: Serpin B9-armored MSLN-CAR T cells show increased tumor cell killing.
a, Western blot showing the expression of endogenous Serpin B9 and EGFP-Serpin B9 in MSLN-CAR T and Se9-MSLN-CAR T cells using the anti-Serpin B9 antibody. The second-generation anti-MSLN CAR retroviral construct, which included EGFP reporter was used in this study (see ‘Methods’). Experiments consisted of three biologically independent samples with similar results. b, Flow cytometric analysis showing the transfection efficiency of mouse MSLN-CAR T cells and Se9-MSLN-CAR T cells. Experiments consisted of three biologically independent samples. c, Se9-MSLN-CAR T cells showed stronger killing of 4662 cells compared to MSLN-CAR T cells. Experiments consisted of three biologically independent samples. d, Growth curves of tumors in mice with UTD T, MSLN-CAR T and Se9-MSLN-CAR T treatments, respectively (n = 5). e, MSLN-CAR T or Se9-MSLN-CAR T cell treatment did not show a significant difference in the body weights of 4662 tumor-bearing mice (n = 5). Data represent mean ± SD (n = 3 or indicated). Statistical analysis was performed using two-sided unpaired t-tests (b, c) or one-way ANOVA with Dunnett’s multiple comparison tests (e).
